RespireRx Pharmaceuticals Inc.

RSPI US

RSPI USRespireRx Pharmaceuticals Inc.

United States Composite

0.00

USD

- -

-0.01EPS Dil.

-NaNMarket Cap

Dividend Date

January 6

Held by Insiders

6.63%

Short % of Float

0.60%

Use logarithmic scale

	2010 Y	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	TTM
Revenue per Share	455.37	124.58	1.46	- -	1.05	0.74	- -	- -	- -	- -	- -	- -	- -	- -
Basic EPS, GAAP	70.81	-90.21	-229.46	-27.31	-216.41	-50.58	-49.63	-17.73	-7.74	-5.41	-0.02	-0.04	-0.02	-0.01
Free Cash Flow per Basic Share	55.99	-77.43	-56.58	-4.15	-15.33	-11.01	-7.14	-2.88	-1.28	-1.25	- -	-0.01	- -	- -
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Book Value per Share	-4,934.81	-4,641.67	-2,913.57	-2,940.88	-2,001.11	-981.98	-732.6	-527.03	-424.78	-398.35	-2.4	-1.78	-1.4	-0.59
Tangible Book Value per Share	99.23	25.16	-68.49	-95.68	-43.59	-20.81	-25.65	-14.26	-14.87	-17.86	-0.11	-0.1	-0.09	-0.04
Basic Weighted Avg Shares	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	259	88	111	174
Sales/Revenue/Turnover	10	3	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Operating Margin (%)	20.83	-72.63	-5,640.75	- -	-7,059.75	-6,028.37	- -	- -	- -	- -	- -	- -	- -	- -
Depreciation Expense	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Net Income, GAAP	2	-2	-8	-1	-3	-6	-9	-4	-3	-2	-4	-3	-2	-2
Effective Tax Rate (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Profit Margin (%)	15.55	-72.41	-15,674.6	- -	-4,390.57	-6,859.37	- -	- -	- -	- -	- -	- -	- -	- -
Working Capital	2	1	-3	-4	-2	-3	-6	-4	-6	-7	-8	-10	-12	-12
LT Debt	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Total Equity	2	1	-3	-4	-2	-3	-5	-4	-6	-7	-8	-10	-12	-12
Return on Invested Capital (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Return on Capital (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Return on Common Equity (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	- -	- -	- -
Net Income, GAAP	14.81%	-2.93%	-33.14%
Free Cash Flow	28.59%	-3.59%	-84.95%
Total Cash Common Dividend	- -	- -	- -
Total Equity	20.65%	22.52%	18.71%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Dr. Arnold S. Lippa Ph.D.
Full Time Employees: 2
Sector: Healthcare
Industry: Biotechnology
Address: 126 Valley Road Glen Rock NJ United States 07452
IPO Date: Nov 6, 1989
Website: www.respirerx.com
Business: RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company's lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and various orphan indications. It has a research collaboration with University College London to the use of AMPAkines for the treatment of GRIA disorders. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey.

	Mar'23	Jun'23	Sep'23
ST Debt	3	3	3
LT Borrowings	- -	- -	- -
LT Finance Leases	- -	- -	- -
Preferred Equity and Hybrid Capital	- -	1	1
Shares Outstanding	144	221	298
Market Capitalization	- -	- -	- -

	2010 Y	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	TTM
Revenue per Share	455.37	124.58	1.46	- -	1.05	0.74	- -	- -	- -	- -	- -	- -	- -	- -
Basic EPS, GAAP	70.81	-90.21	-229.46	-27.31	-216.41	-50.58	-49.63	-17.73	-7.74	-5.41	-0.02	-0.04	-0.02	-0.01
Free Cash Flow per Basic Share	55.99	-77.43	-56.58	-4.15	-15.33	-11.01	-7.14	-2.88	-1.28	-1.25	- -	-0.01	- -	- -
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Book Value per Share	-4,934.81	-4,641.67	-2,913.57	-2,940.88	-2,001.11	-981.98	-732.6	-527.03	-424.78	-398.35	-2.4	-1.78	-1.4	-0.59
Tangible Book Value per Share	99.23	25.16	-68.49	-95.68	-43.59	-20.81	-25.65	-14.26	-14.87	-17.86	-0.11	-0.1	-0.09	-0.04
Basic Weighted Avg Shares	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	259	88	111	174
Sales/Revenue/Turnover	10	3	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Operating Margin (%)	20.83	-72.63	-5,640.75	- -	-7,059.75	-6,028.37	- -	- -	- -	- -	- -	- -	- -	- -
Depreciation Expense	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Net Income, GAAP	2	-2	-8	-1	-3	-6	-9	-4	-3	-2	-4	-3	-2	-2
Effective Tax Rate (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Profit Margin (%)	15.55	-72.41	-15,674.6	- -	-4,390.57	-6,859.37	- -	- -	- -	- -	- -	- -	- -	- -
Working Capital	2	1	-3	-4	-2	-3	-6	-4	-6	-7	-8	-10	-12	-12
LT Debt	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Total Equity	2	1	-3	-4	-2	-3	-5	-4	-6	-7	-8	-10	-12	-12
Return on Invested Capital (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Return on Capital (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Return on Common Equity (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2021	-0.01	-0.01	-0.01	-0.01	-0.04
2022	-0.01	-0.01	- -	- -	-0.02
2023	- -	- -	- -	- -	- -

	Mar'23	Jun'23	Sep'23
Total Current Assets	- -	- -	- -
Accounts Receivable, Net	- -	- -	- -
Cash, Cash Equivalents & STI	- -	- -	- -
Inventories	- -	- -	- -
Total Current Liabilities	12	12	12
Payables & Accruals	6	6	7
ST Debt	3	3	3
Deferred Revenue	- -	- -	- -